Fri, Jul 25, 2014, 3:16 PM EDT - U.S. Markets close in 44 mins.

Recent

% | $
Click the to save as a favorite.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • wilderguide wilderguide Jun 25, 2013 6:06 PM Flag

    Dr. Shaw on Crizotinib Versus Chemotherapy in ALK-Positive NSCLC

    $$$$
    Onlive today 6/25/13....
    Getting the clinical mojo to stage with Crizotinib is the best thing that can happen to ganetespib...
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This may well may well have been the driving force behind all of SNTA's Insider Buying.

      Insider buying started on June 4th and has continued , I believe that article came out on June 1st which was a Sat,

      • 1 Reply to lilgodfther
      • $$$$
        "This may well may well have been the driving force behind all of SNTA's Insider Buying"

        Perhaps...but I see another "sleeper" in NCT01551693. It is a P2 trial of Ganetespib in advanced melanoma. Trial enrollment is only projected at 50, with a data collection date of June 2013. Recently published findings from Moffitt Cancer Center in Florida suggest strong rationale for HSP90i in combination with Zelboraf. They are working with XL-888, the HSP90i from EXEL. XL-888 is thought to overcome BRAF inhibitor resistance. It wouldn't surprise me that G has the same capacity. The Moffitt study is still in P1...

        If the P2 melanoma NCT01551693 reports a reasonable OS signal of G monotherapy, I would expect to soon see a P3 trial both G monotherapy and (quite possibly) in combination with Z (vemurafinib) Makes sense to capitalize on existing published research, and might also account for the recent lively run-up of insider buying.
        GLTA

 
SNTA
4.0413-0.0487(-1.19%)3:15 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.